The mission of Microgen is to become a leader in the development and manufacturing of novel diagnostic tests for public health applications. Currently, we are focused on the commercialization of infectious disease point-of-care diagnostics that are rapid, inexpensive, and simple to use.
Copyright © 2024 Microgen Laboratories. All Rights Reserved.
Dr. Raymond Stowe CEO directs Microgen Laboratories’s analytical and research programs. Dr. Stowe received his B.S. in microbiology from Stephen F. Austin State University. He then worked at NASA-Johnson Space Center where he co-developed projects to study the effects of stress and spaceflight on cell-mediated immunity and reactivation of latent viral infections in astronauts, funded by a NASA fellowship. He subsequently received his PhD in the Experimental Pathology program at the University of Texas Medical Branch, where he specialized in molecular immunology and virology. Dr. Stowe has authored numerous articles and has been either PI and Co-I on several federal and non-federal grants and contracts.
Ms. Robin Huff Stowe, President and CIO, implements Microgen’s technology strategy and handles its day-to-day operations. Ms. Stowe previously served as the Chemical Stream Coordinator for Documentum Implementation at BP and possesses over twenty-five years of experience in Project Management, Business Process Reengineering, and Data Management. Ms. Stowe received her B.S. in Computer Science from Trinity University in San Antonio, Texas.
Dr. Kommineni is responsible for Quality Management and Quality Assurance. She maintains Quality systems and coordinates with Regulatory Affairs to get Medical Device and Diagnostics kits into the market. Dr. Kommineni obtained her Ph.D. in Biochemistry from Central University of Hyderabad, India. She did post-doctoral training on Gene Therapy at Texas A&M University, College Station, TX, where she developed site-specific integration of genes by using DNA binding domains. Prior to joining Microgen, Dr. Kommineni served as Director of Assay Development for iBio CDMO and Group Leader of Biologics III in Catalent Pharma Solutions, Kansas City, MO. Dr Kommineni worked on several cancer and viral therapeutics, protein and Glyco-engineering of therapeutics to improve the efficacy and several assay method developments and validation studies. She also led viral therapeutics assay development services. Prior to that, she served as Project Manager/Research Specialist-V for ‘Texas Department of State Health Services (DSHS)’ and coordinated in implementing new screening methods in ‘Newborn screening program’. She holds US provisional patent, several publications in peer reviewed journals and book chapters.
